
    
      Non-interventional, multi-center, long-term follow-up (LTFU) study of subjects dosed with
      SB-318 in the clinical study SB-318-1502, SB-913 in the clinical study SB-913-1602, and
      SB-FIX in clinical study SB-FIX-1501. All subjects dosed in the studies and completed at
      least 52 weeks post-infusion follow-up in their primary protocol will be offered to
      participate. Subjects who enroll will be monitored for a total of up to 10 years following
      exposure to the respective investigational products.
    
  